“Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials”, J of Skin, vol. 8, no. 6, p. s419, Nov. 2024, doi: 10.25251/skin.8.supp.419.